1998 Volume 46 Issue 3 Pages 119-125
We evaluated the clinical efficacy and safety of sulbactam/ampicillin (SBT/ABPC), β-lactamase inhibitor, for patients with respiratory tract infections who had visited our hospital as Kasaoka Daiichi Hospital for treatment and as Kawasaki Medical School Hospital and compared the two patient groups. More patients who visited our hospital as Kawasaki Medical School Hospital had already received treatment with different antibiotics, had underlying diseases (especially respiratory diseases), and were in a poor nutritive state as compared with those visiting our hospital as Kasaoka Daiichi Hospital. Regarding the relationship between efficacy rate and infectious type, 22 were of the community acquired infectious type, and 11 cases (12 episodes) were of the nosocomial infectious type and the efficacy rate was lower (71%) for patients for whom our hospital was Kawasaki Medical School Hospital. The efficacy rate for patients at Kawasaki Medical School Hospital with infection of community acquired type only was 82%. Most patients who visited our hospital as Kasaoka Daiichi Hospital had infections of the community acquired infectious type, and the efficacy rate was high (96%). As to side effects, drug-induced pneumonitis and drug fever, respectively, were observed in two patients for whom our hospital was Kawasaki Medical School Hospital. In laboratory tests, transient slight transaminase elevation or eosinophilia was observed in four patients visiting our hospital as Kawasaki Medical School Hospital, and in six patients visiting it as Kasaoka Daiichi Hospital. Sulbactam/ampicillin is an effective initial therapy for respiratory tract infections of the community acquired infectious type, but careful observation is also necessary for patients during the administration of sulbactam/ampicillin.
